



KOLINPHARMA®
LEADER TO HEALTH

KOLINPHARMA®: SIGNED A FIRST FACTORING PRO-SOLUTO AGREEMENT UP TO EUR 2 MILLION

Milan, June 22nd 2018

KOLINPHARMA®, Innovative SME operating in the nutraceutical sector, communicates the subscription of a factoring pro-soluto agreement with Banca IFIS S.p.A., for a total amount of EUR 2 million.

This new contract raises the bank's reliance from EUR 1.35 million as of 12-31-2017, as written on the Admission Document, to a total amount of EUR 3.35 million today. This improves the KOLINPHARMA®'s bank rating and it will provide to the Company further resources to keep on pursuing the strategic guidelines announced during the listing, based on investments for research and development of new products and new pharmaceutical forms, in addition to the sales network's reinforcement.

Rita Paola Petrelli, KOLINPHARMA®'s Chairwoman, declared: "this agreement confirms the interest in a nutraceutical and Innovative SME, not only by capital markets, but also by the bank world. The subscription of this contract will provide the company more liquidity to be allocated to operational activities, looking at the expected growth of our development strategic path".

The factoring pro-soluto is a transfer to a bank (factor) of commercial credits against an immediate collection of these, anticipating the usual recovery times, neutralising possible losses on clients who burden on the company.

This press release is available online on our corporate website www.kolinpharma.com, in the section Investor Relations > Financial Press Releases.

KOLINPHARMA® S.p.A., founded in 2013, is an Innovative SME operating in nutraceutical sector and specialised in the research and development, realised internally and in collaboration with the major Italian universities. The Company's products are made of innovative and natural raw materials and have the purpose of supporting the pharmacological treatments mainly for the diseases in the orthopaedic-physiatric and gynaecological fields. KOLINPHARMA distributes the products with its brand in the whole Italian territory through a skilled sales network of 66 medical-scientific representatives (MSRs), specialised sole agents graduated in scientific disciplines. The MSRs promote KOLINPHARMA's nutraceutical products directly to doctors, pointing at the specialists' awareness. The Company's direct clients are wholesalers, that distribute to pharmacies and para-pharmacies throughout Italy. KOLINPHARMA owns 4 patents in Italy and 9 certifications, of which 2 on the company and 7 on its products.

Contacts

IR TOP Consulting S.r.l
Capital Markets & Investor Relations
Floriana Vitale, Domenico Gentile
f.vitale@irtop.com , d.gentile@irtop.com
Via C. Cantù, 1 - 20123 Milan
Tel.: +39 02 4547 3883/4

EnVent Capital Markets Ltd.
Nominated Adviser (NOMAD)
Francesca Martino
fmartino@enventcapitalmarkets.co.uk
42 Berkeley Square - London W1J 5AW Italian
Branch, via Barberini n. 95 - 00187 Rome
Tel.: +39 06 896841 Fax: +39 06 89684155

